The Myositis – Sirolimus in IBM trial is open to patients with a confirmed diagnosis of IBM, aged 45 years and older. Participants are required to take the study drug (Sirolimus or placebo) every day for 18 months. Participants are randomly assigned to the placebo or study drug group, neither the participant nor the study team will know which treatment has been assigned until the end of the study.
14 sites are recruiting to this study, based in Australia, US, UK, and Europe, with 10 participants per site.
For more information on the study including further information for what is involved contact the study team listed under the ‘Enquiries’ heading.